PULMONX CORP (LUNG) Fundamental Analysis & Valuation

NASDAQ:LUNG • US7458481014

Current stock price

1.29 USD
+0.01 (+0.78%)
At close:
1.3523 USD
+0.06 (+4.83%)
After Hours:

This LUNG fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. LUNG Profitability Analysis

1.1 Basic Checks

  • LUNG had negative earnings in the past year.
  • LUNG had a negative operating cash flow in the past year.
  • In the past 5 years LUNG always reported negative net income.
  • LUNG had a negative operating cash flow in each of the past 5 years.
LUNG Yearly Net Income VS EBIT VS OCF VS FCFLUNG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • LUNG has a Return On Assets of -41.77%. This is in the lower half of the industry: LUNG underperforms 64.36% of its industry peers.
  • Looking at the Return On Equity, with a value of -99.79%, LUNG is doing worse than 63.83% of the companies in the same industry.
Industry RankSector Rank
ROA -41.77%
ROE -99.79%
ROIC N/A
ROA(3y)-36.87%
ROA(5y)-32.35%
ROE(3y)-72.31%
ROE(5y)-56.08%
ROIC(3y)N/A
ROIC(5y)N/A
LUNG Yearly ROA, ROE, ROICLUNG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

1.3 Margins

  • Looking at the Gross Margin, with a value of 74.19%, LUNG belongs to the top of the industry, outperforming 83.51% of the companies in the same industry.
  • LUNG's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for LUNG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.05%
GM growth 5Y2.75%
LUNG Yearly Profit, Operating, Gross MarginsLUNG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. LUNG Health Analysis

2.1 Basic Checks

  • LUNG does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • LUNG has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, LUNG has more shares outstanding
  • The debt/assets ratio for LUNG is higher compared to a year ago.
LUNG Yearly Shares OutstandingLUNG Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
LUNG Yearly Total Debt VS Total AssetsLUNG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • LUNG has an Altman-Z score of -5.08. This is a bad value and indicates that LUNG is not financially healthy and even has some risk of bankruptcy.
  • LUNG has a Altman-Z score of -5.08. This is in the lower half of the industry: LUNG underperforms 71.28% of its industry peers.
  • LUNG has a Debt/Equity ratio of 0.68. This is a neutral value indicating LUNG is somewhat dependend on debt financing.
  • LUNG's Debt to Equity ratio of 0.68 is on the low side compared to the rest of the industry. LUNG is outperformed by 68.62% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF N/A
Altman-Z -5.08
ROIC/WACCN/A
WACC8.02%
LUNG Yearly LT Debt VS Equity VS FCFLUNG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 5.07 indicates that LUNG has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 5.07, LUNG is doing good in the industry, outperforming 75.53% of the companies in the same industry.
  • LUNG has a Quick Ratio of 4.28. This indicates that LUNG is financially healthy and has no problem in meeting its short term obligations.
  • LUNG's Quick ratio of 4.28 is fine compared to the rest of the industry. LUNG outperforms 74.47% of its industry peers.
Industry RankSector Rank
Current Ratio 5.07
Quick Ratio 4.28
LUNG Yearly Current Assets VS Current LiabilitesLUNG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. LUNG Growth Analysis

3.1 Past

  • LUNG shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.00%.
  • Looking at the last year, LUNG shows a quite strong growth in Revenue. The Revenue has grown by 8.01% in the last year.
  • Measured over the past years, LUNG shows a very strong growth in Revenue. The Revenue has been growing by 22.56% on average per year.
EPS 1Y (TTM)5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.24%
Revenue 1Y (TTM)8.01%
Revenue growth 3Y19.03%
Revenue growth 5Y22.56%
Sales Q2Q%-4.91%

3.2 Future

  • LUNG is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.86% yearly.
  • LUNG is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 32.55% yearly.
EPS Next Y-2.46%
EPS Next 2Y10%
EPS Next 3Y22.63%
EPS Next 5Y32.86%
Revenue Next Year1.35%
Revenue Next 2Y9.57%
Revenue Next 3Y20.03%
Revenue Next 5Y32.55%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LUNG Yearly Revenue VS EstimatesLUNG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
LUNG Yearly EPS VS EstimatesLUNG Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 6 8

More info and screens

Find the best growth stocksShow best growing peers

1

4. LUNG Valuation Analysis

4.1 Price/Earnings Ratio

  • LUNG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LUNG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LUNG Price Earnings VS Forward Price EarningsLUNG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LUNG Per share dataLUNG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as LUNG's earnings are expected to grow with 22.63% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10%
EPS Next 3Y22.63%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LUNG Dividend Analysis

5.1 Amount

  • LUNG does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LUNG Fundamentals: All Metrics, Ratios and Statistics

PULMONX CORP

NASDAQ:LUNG (4/8/2026, 8:00:00 PM)

After market: 1.3523 +0.06 (+4.83%)

1.29

+0.01 (+0.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-04
Earnings (Next)04-28
Inst Owners82.2%
Inst Owner Change0%
Ins Owners10.71%
Ins Owner Change39.92%
Market Cap54.49M
Revenue(TTM)90.50M
Net Income(TTM)-54.00M
Analysts80
Price Target5.27 (308.53%)
Short Float %8.81%
Short Ratio6.11
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.9%
Min EPS beat(2)20.32%
Max EPS beat(2)37.48%
EPS beat(4)4
Avg EPS beat(4)15.83%
Min EPS beat(4)0.21%
Max EPS beat(4)37.48%
EPS beat(8)8
Avg EPS beat(8)19.39%
EPS beat(12)12
Avg EPS beat(12)15.75%
EPS beat(16)15
Avg EPS beat(16)12.27%
Revenue beat(2)2
Avg Revenue beat(2)1.49%
Min Revenue beat(2)1.01%
Max Revenue beat(2)1.96%
Revenue beat(4)3
Avg Revenue beat(4)0.73%
Min Revenue beat(4)-0.33%
Max Revenue beat(4)1.96%
Revenue beat(8)6
Avg Revenue beat(8)1.31%
Revenue beat(12)10
Avg Revenue beat(12)2.62%
Revenue beat(16)12
Avg Revenue beat(16)2.64%
PT rev (1m)-10.14%
PT rev (3m)-10.14%
EPS NQ rev (1m)3.92%
EPS NQ rev (3m)3.92%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-7.75%
Revenue NQ rev (3m)-7.75%
Revenue NY rev (1m)-3.51%
Revenue NY rev (3m)-3.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.6
P/FCF N/A
P/OCF N/A
P/B 1.01
P/tB 1.05
EV/EBITDA N/A
EPS(TTM)-1.33
EYN/A
EPS(NY)-1.36
Fwd EYN/A
FCF(TTM)-0.78
FCFYN/A
OCF(TTM)-0.77
OCFYN/A
SpS2.14
BVpS1.28
TBVpS1.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -41.77%
ROE -99.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.19%
FCFM N/A
ROA(3y)-36.87%
ROA(5y)-32.35%
ROE(3y)-72.31%
ROE(5y)-56.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.05%
GM growth 5Y2.75%
F-Score3
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.88%
Cap/Sales 0.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.07
Quick Ratio 4.28
Altman-Z -5.08
F-Score3
WACC8.02%
ROIC/WACCN/A
Cap/Depr(3y)63.98%
Cap/Depr(5y)140.24%
Cap/Sales(3y)1.13%
Cap/Sales(5y)2.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.24%
EPS Next Y-2.46%
EPS Next 2Y10%
EPS Next 3Y22.63%
EPS Next 5Y32.86%
Revenue 1Y (TTM)8.01%
Revenue growth 3Y19.03%
Revenue growth 5Y22.56%
Sales Q2Q%-4.91%
Revenue Next Year1.35%
Revenue Next 2Y9.57%
Revenue Next 3Y20.03%
Revenue Next 5Y32.55%
EBIT growth 1Y7.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year46.77%
EBIT Next 3Y11.4%
EBIT Next 5YN/A
FCF growth 1Y0.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2.66%
OCF growth 3YN/A
OCF growth 5YN/A

PULMONX CORP / LUNG Fundamental Analysis FAQ

What is the fundamental rating for LUNG stock?

ChartMill assigns a fundamental rating of 3 / 10 to LUNG.


Can you provide the valuation status for PULMONX CORP?

ChartMill assigns a valuation rating of 1 / 10 to PULMONX CORP (LUNG). This can be considered as Overvalued.


How profitable is PULMONX CORP (LUNG) stock?

PULMONX CORP (LUNG) has a profitability rating of 1 / 10.


How financially healthy is PULMONX CORP?

The financial health rating of PULMONX CORP (LUNG) is 3 / 10.


What is the earnings growth outlook for PULMONX CORP?

The Earnings per Share (EPS) of PULMONX CORP (LUNG) is expected to decline by -2.46% in the next year.